Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Paolo Palmisciano
 + 1599 word(s) 1599 2021-12-29 07:35:26 |
2 The format is correct
Lindsay Dong
 Meta information modification 1599 2022-01-12 07:44:23 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Palmisciano, P. Orbital Metastases. Encyclopedia. Available online: https://encyclopedia.pub/entry/18046 (accessed on 02 September 2024).
Palmisciano P. Orbital Metastases. Encyclopedia. Available at: https://encyclopedia.pub/entry/18046. Accessed September 02, 2024.
Palmisciano, Paolo. "Orbital Metastases" Encyclopedia, https://encyclopedia.pub/entry/18046 (accessed September 02, 2024).
Palmisciano, P. (2022, January 11). Orbital Metastases. In Encyclopedia. https://encyclopedia.pub/entry/18046
Palmisciano, Paolo. "Orbital Metastases." Encyclopedia. Web. 11 January, 2022.
Orbital Metastases
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers14010094

Orbital metastases may significantly worsen the functional status of oncological patients, leading to debilitating visual impairments. Surgical resection, orbital exenteration, and complementary therapies may result in heterogeneous clinical outcomes. Most orbital metastases occur at later stages after primary tumors, frequently showing diffuse location within the orbit and rarely invading intracranial structures. Biopsy-only techniques were more frequently preferred in view of the less invasive approaches, but surgical resection and orbital radiotherapy were related to improved clinical outcomes. Although patients with primary breast cancer and patients undergoing resection showed superior prognoses, overall survival rates were generally poor, suggesting the need to better understand orbital metastases’ microenvironments for devising optimal systemic treatment strategies.

orbital exenteration orbital metastases radiation oncology skull base oncology

1. Introduction

Orbital metastases represent 1–13% of all orbital neoplasms and affect approximately 2–5% of patients with systemic malignancies [1][2][3]. Breast, melanoma, and prostate cancers comprise the prevalent primary tumors, and their incidence is increasing due to improved surveillance, systemic disease control and management of oncological patients [3][4][5]. Orbital metastases can often be detected in those with no previous history of cancer due to their common presenting of symptoms of visual disturbance, thus preceding the diagnosis of primary tumors [4][6]. Common presenting symptoms include diplopia, ocular pain, and vision loss, coupled with globe displacement and palpable orbital masses [7][8]. Metastases frequently appear on imaging as irregular and contrast-enhancing lesions in the anterior orbit involving bones and extraocular muscles [8][9][10].
Treatment strategies depend on the clinical presentation and primary tumor pathology; however, a gold standard for treatment has yet to be defined [3][11]. In poor surgical candidates, orbital irradiation can be utilized to facilitate reduction in tumor volume and symptom relief [12]. Surgical debulking is effective in decreasing mass-effect and improving symptoms but can also lead to serious complications such as permanent visual deficits [13]. Chemotherapy, hormonal therapy, and/or targeted therapy have the benefit of simultaneous control of primary and metastatic lesions [7][9].
There is a limited number of individual studies on orbital metastases, and feasible therapeutic options are still debated [14][15].

2. Orbital Metastases

Surgical tumor resection significantly increased symptom relief and survival compared to biopsy-only. While orbital radiotherapy may effectively prevent tumor progression in the long term, the role of advanced systemic therapies requires further evaluation.

Although some differences in primary tumors have been reported between studies, probably mirroring the underlying geographic variations of cancer rates, breast cancer (36.3%), melanoma (10.1%) and prostate cancer (8.5%) were the most frequent [3][4][5]. Similar prevalence rates have been reported for patients with uveal metastases, likely suggesting common routes of tumoral hematogenous spread and organotrophic seeding to both ocular and orbital structures [16][17][18][19]. The true incidence of orbital metastases from primary tumors may be difficult to ascertain only from clinical series of patients with histopathology reports, paving the way to a detection bias in the data collection for this paper. Cancers with more aggressive disease courses may rapidly metastasize to multiple major organs besides the orbit, severely debilitating patient functional status and thus making histological confirmation of suspected orbital metastases unnecessary. This likely explains the lower rates of primary lung cancers (5.6%) compared to other tumors such as carcinoid (6.6%). Indeed, carcinoids are less common malignancies, but they often show better prognoses and slower disease courses, with rare concurrent systemic metastases [5][8]. The median time interval between primary tumor diagnosis and the onset of orbital metastases was 12 months, further reflecting the long-lasting process of metastatic seeding into the orbit. In line with the literature on patients with choroidal metastases, the detection of orbital lesions preceded the primary tumor diagnosis in 30.1% of patients, with 37 cases of CUPs (4.2%). CUPs represent metastatic carcinomas with no primary neoplasms identified at diagnostic workup and mostly deriving from older case series [3][20][21][22][23][24]. More recently, upfront whole-body PET/CT scans are frequently recommended in patients with no history of cancer and clinical suspicion of orbital or intraocular metastases to expedite management and systemic treatments [6][25][26].

As opposed to benign orbital tumors, orbital metastases frequently manifest clinically with an abrupt onset of rapidly progressive symptoms [1][27]. Most metastases occurred unilaterally and diffusely infiltrated intra/extraconal orbital soft tissues, causing globe displacement with proptosis, diplopia and impaired eye motility [3][4][5]. The direct compression of the optic nerve, commonly at the orbital apex, additionally led to RAPD and vision decline, with a serious impact on patients’ functional status [28][29]. Less frequently, paradoxical enophthalmos of the affected eye resulted from the infiltration of neoplastic cells into the extraocular muscles and retro-bulbar stromal tissues causing desmoplasia, fibrosis and globe retraction [30][31][32]. Some ocular symptoms, such as visual impairments and periocular pain, may share similarities between orbital and choroidal metastases, thus requiring further assessment with orbital imaging [7][33].

This is especially the case in patients with no evident orbital or ocular masses. Some primary cancers tend to infiltrate specific orbital tissues, such as breast cancers localizing within the orbital fat pad due to the local hormonal patterns, and melanomas invading and enlarging the extraocular muscles as seen clearly on MRI scans [34][35]. Similarly, prostate and liver cancers commonly infiltrate the orbital bony structures inducing osteoblastic or osteoclastic reactions, and this is better identified on CT scans [7][36].

Both incisional and fine-needle aspiration biopsy showed no benefits in clinical and survival outcomes but were chosen over tumor resection in most patients. On par with choroidal metastases, biopsy of suspected orbital metastases is often required for differential diagnosis in patients with no cancer history or for histomolecular characterization when biopsy of other metastatic sites is less viable [6][37]. When surgery is not deemed feasible, biopsy represents a safe alternative advantageous to initiate systemic therapy; however, tumor resection should be preferred in eligible patients. Indeed, tumor debulking, regardless of the extent-of-resection, led to significant clinical (p = 0.005), radiological (p = 0.007), and survival (p = 0.004) improvement when compared to biopsy. The mechanism for this result may likely be the prompt decompression with relief of mass effect and decrease in tumor burden with increased effectiveness of complementary therapies [14][34][38]. 

Regarding orbital exenteration, there is no survival benefit compared to patients undergoing orbital-preserving complete tumor resection (p = 0.153). Such a finding substantiates once again that survival is more likely affected by systemic disease control than metastasis-directed local therapy. Orbital exenteration is often considered for treating aggressive craniofacial malignancies with orbital infiltration and perineural invasion, effectively reducing rates of local recurrences and re-operations [39][40]. In orbital metastases, the limited benefit of orbital exenteration is likely due to the underlying systemic spreading of tumor cells and related poor prognoses [41][42]. Hence, orbital exenteration may be unnecessary for treating orbital metastases in patients with systemic malignancies, and thus surgery should be intended to preserve acceptable quality of life while avoiding highly disfiguring procedures. However, orbital exenteration may play a role in providing relief of severe orbital pain in patients with already poor or absent pre-operative vision function [3][4][34].

In some cases, orbital metastases may extend intracranially into the anterior and middle cranial fossa, similarly to other craniofacial malignancies such as nasopharyngeal carcinomas. Still, a more in-depth evaluation of specific tumor microenvironments is highly encouraged to identify favorable therapeutic targets and support less-invasive treatment strategies specifically for patients with cranio-orbital metastases.

Radiotherapy is a well-established palliative therapeutic option for benign and malignant orbital lesions, as well as for periocular ones [11][12][27][43][44][45]. In line with previous reports on choroidal metastases, radiotherapy significantly ameliorates clinical and functional status in patients with orbital metastases (p = 0.032), favoring nonsurgical lesion shrinkage and relief of mass effect [17][46]. Although some cases of radiation-induced cataracts have been reported in earlier studies [47], modern image-guided radiotherapy planning allows the delivery of maximal doses to selected targets [48][49], sparing critical orbital structures and preventing the onset of severe adverse events [47][50][51][52]. Thus, radiotherapy appears to be safe and effective in the treatment of orbital metastases similarly to choroidal metastases, but the severity of radiation-induced complications might differ due to the unfortunate proximity of choroidal metastases to the macula and lens [46][53]. The usefulness of particle therapy, a type of radiotherapy characterized by a peculiarly beneficial dose distribution to the target (Bragg peak), to maximize the sparing of critical ocular structures with respect to the photon-based radiotherapy needs to be further investigated to evaluate its cost effectiveness [54][55]. However, particle therapy has not a widespread distribution, and classic radiotherapy could be more easily accessible. In such critical anatomical sites, safely delivering a high ablative dose in those tumor layers more distantly located from organs at risk while gradually underdosing the successive ones might have a radiobiological rationale in addition to a potentially successful effect. This approach with partial tumor irradiation or with spatially fractionation of the radiation dose is just a hypothesis because it has been effectively tested only for treatment of bulky tumors at different body sites from those examined here [56][57].

The prognosis of patients with orbital metastases is poor with one-year survival rates, (40%) lower than patients with choroidal metastases (52%) and comparable to patients with brain metastases (39–46%), implying that their occurrence is more frequent at the very advanced disease stages, which call for an effective improvement in current systemic therapeutic strategies [17][58][59][60].

3. Conclusions

Orbital metastases are rare, debilitating lesions in oncological patients. Histopathological examination is recommended to guide complementary therapeutic protocols, but surgery is often challenging. Tumor resection, regardless of its extent, showed improved clinical and survival outcomes over biopsy, but the impact of underlying clinical and tumor characteristics should be still considered on a case-by-case basis before planning surgical strategies. Orbital exenteration appears less useful when used in addition to complete tumor resection because no survival benefit was found. Furthermore, the positive clinical impact of orbital radiotherapy may favor its implementation in patients not eligible to undergo surgery or who underwent a subtotal resection. Future prospective studies are required to better understand the role of multimodal systemic therapeutic strategies in the management of orbital metastases based on primary tumor histopathology.

References

  1. Shields, J.A.; Shields, C.L.; Scartozzi, R. Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1. Ophthalmology 2004, 111, 997–1008.
  2. Bonavolontà, G.; Strianese, D.; Grassi, P.; Comune, C.; Tranfa, F.; Uccello, G.; Iuliano, A. An Analysis of 2480 Space-Occupying Lesions of the Orbit from 1976 to 2011. Ophthalmic Plast. Reconstr. Surg. 2013, 29, 79–86.
  3. Magliozzi, P.; Strianese, D.; Bonavolontà, P.; Ferrara, M.; Ruggiero, P.; Carandente, R.; Bonavolontà, G.; Tranfa, F. Orbital metastases in Italy. Int. J. Ophthalmol. 2015, 8, 1018–1023.
  4. Valenzuela, A.A.; Archibald, C.W.; Fleming, B.; Ong, L.; O’Donnell, B.; Crompton, J.J.; Selva, D.; McNab, A.A.; Sullivan, T.J. Orbital Metastasis: Clinical Features, Management and Outcome. Orbit 2009, 28, 153–159.
  5. Eldesouky, M.A.; Elbakary, M.A. Clinical and imaging characteristics of orbital metastatic lesions among Egyptian patients. Clin. Ophthalmol. 2015, 9, 1683–1687.
  6. Allen, R. Orbital metastases: When to suspect? When to biopsy? Middle East Afr. J. Ophthalmol. 2018, 25, 60.
  7. Ahmad, S.M.; Esmaeli, B. Metastatic tumors of the orbit and ocular adnexa. Curr. Opin. Ophthalmol. 2007, 18, 405–413.
  8. Kamieniarz, L.; Armeni, E.; O’Mahony, L.F.; Leigh, C.; Miah, L.; Narayan, A.; Bhatt, A.; Cox, N.; Mandair, D.; Navalkissoor, S.; et al. Orbital metastases from neuroendocrine neoplasms: Clinical implications and outcomes. Endocrine 2020, 67, 485–493.
  9. Shields, J.A.; Shields, C.L.; Brotman, H.K.; Carvalho, C.; Perez, N.; Eagle, R.C. Cancer Metastatic to the Orbit. Ophthal. Plast. Reconstr. Surg. 2001, 17, 346–354.
  10. Tailor, T.D.; Gupta, D.; Dalley, R.W.; Keene, C.D.; Anzai, Y. Orbital Neoplasms in Adults: Clinical, Radiologic, and Pathologic Review. RadioGraphics 2013, 33, 1739–1758.
  11. Wladis, E.J.; Lee, K.W.; Nazeer, T. Metastases of systemic malignancies to the orbit: A major review. Orbit 2021, 40, 93–97.
  12. Ioakeim-Ioannidou, M.; MacDonald, S.M. Evolution of Care of Orbital Tumors with Radiation Therapy. J. Neurol. Surg. Part B Skull Base 2020, 81, 480–496.
  13. Newman, S.A. Orbital Surgery: Evolution and Revolution. J. Neurol. Surg. Part B Skull Base 2021, 82, 7–19.
  14. Tsagkaraki, I.M.; Kourouniotis, C.D.; Gomatou, G.L.; Syrigos, N.K.; Kotteas, E.A. Orbital metastases of invasive lobular breast carcinoma. Breast Dis. 2019, 38, 85–91.
  15. Sklar, B.A.; Gervasio, K.A.; Karmazin, K.; Wu, A.Y. Orbital Metastasis From Urothelial Carcinoma: A Comprehensive Literature Review. Ophthalmic Plast. Reconstr. Surg. 2019, 35, 213–217.
  16. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133, 571–573.
  17. D’Abbadie, I.; Arriagada, R.; Spielmann, M.; Lê, M.G. Choroid metastases: Clinical features and treatments in 123 patients. Cancer 2003, 98, 1232–1238.
  18. Arepalli, S.; Kaliki, S.; Shields, C.L. Choroidal metastases: Origin, features, and therapy. Indian J. Ophthalmol. 2015, 63, 122–127.
  19. Konstantinidis, L.; Damato, B. Intraocular Metastases—A Review. Asia-Pac. J. Ophthalmol. 2017, 6, 208–214.
  20. Huh, S.H.; Nisce, L.Z.; Simpson, L.D.; Chu, F.C.H. Value of radiation therapy in the treatment of orbital metastases. Am. J. Roentgenol. 1974, 120, 589–594.
  21. Char, D.H.; Miller, T.; Kroll, S. Orbital metastases: Diagnosis and course. Br. J. Ophthalmol. 1997, 81, 386–390.
  22. Holland, D.; Maune, S.; Kovács, G.; Behrendt, S. Metastic tumors of the orbit: A retrospective study. Orbit 2003, 22, 15–24.
  23. Shields, C.L.; Shields, J.A.; Gross, N.E.; Schwartz, G.P.; Lally, S.E. Survey of 520 Eyes with Uveal Metastases. Ophthalmology 1997, 104, 1265–1276.
  24. Amer, R.; Pe’er, J.; Chowers, I.; Anteby, I. Treatment Options in the Management of Choroidal Metastases. Ophthalmologica 2004, 218, 372–377.
  25. Das, S.; Pineda, G.; Goff, L.; Sobel, R.; Berlin, J.; Fisher, G. The eye of the beholder: Orbital metastases from midgut neuroendocrine tumors, a two institution experience. Cancer Imaging 2018, 18, 1–7.
  26. Mathis, T.; Jardel, P.; Loria, O.; Delaunay, B.; Nguyen, A.; Lanza, F.; Mosci, C.; Caujolle, J.-P.; Kodjikian, L.; Thariat, J. New concepts in the diagnosis and management of choroidal metastases. Prog. Retin. Eye Res. 2019, 68, 144–176.
  27. Laplant, J.; Cockerham, K. Primary Malignant Orbital Tumors. J. Neurol. Surg. Part B Skull Base 2021, 82, 81–90.
  28. Strachan, K.; Jamieson, A. The relative afferent pupillary defect: Its role in the diagnosis of metastatic malignancy. QJM 2012, 105, 463–466.
  29. Crisostomo, S.; Cardigos, J.; Fernandes, D.H.; Luís, M.E.; Pires, G.N.; Duarte, A.F.; Boavida, A.M. Bilateral metastases to the extraocular muscles from small cell lung carcinoma. Arq. Bras. Oftalmol. 2019, 82, 422–424.
  30. Goldberg, R.A.; Rootman, J. Clinical Characteristics of Metastatic Orbital Tumors. Ophthalmology 1990, 97, 620–624.
  31. Homer, N.; Jakobiec, F.A.; Stagner, A.; Cunnane, M.E.; Freitag, S.K.; Fay, A.; Yoon, M.K. Periocular breast carcinoma metastases: Correlation of clinical, radiologic and histopathologic features. Clin. Experiment. Ophthalmol. 2017, 45, 606–612.
  32. El-Khazen Dupuis, J.; Marchand, M.; Javidi, S.; Nguyen, T.Q.T. Enophthalmos as the Initial Systemic Finding of Undiagnosed Metastatic Breast Carcinoma. Int. Med. Case Rep. J. 2021, 14, 25–31.
  33. Shah, S.U.; Mashayekhi, A.; Shields, C.L.; Walia, H.S.; Hubbard, G.B.; Zhang, J.; Shields, J.A. Uveal Metastasis from Lung Cancer. Ophthalmology 2014, 121, 352–357.
  34. Sindoni, A.; Fama’, F.; Vinciguerra, P.; Dionigi, G.; Manara, S.A.A.M.; Gaeta, R.; Gioffre’-Florio, M.; di Maria, A. Orbital metastases from breast cancer: A single institution case series. J. Surg. Oncol. 2020, 122, 170–175.
  35. Zografos, L.; Ducrey, N.; Beati, D.; Schalenbourg, A.; Spahn, B.; Balmer, A.; Othenin-Girard, C.B.; Chamot, L.; Egger, E. Metastatic melanoma in the eye and orbit. Ophthalmology 2003, 110, 2245–2256.
  36. Eldesouky, M.A.; Elbakary, M.A.; Shalaby, O.E.; Shareef, M.M. Orbital Metastasis From Hepatocellular Carcinoma. Ophthalmic Plast. Reconstr. Surg. 2014, 30, e78–e82.
  37. Shields, J.A.; Shields, C.L.; Ehya, H.; Eagle, R.C.; Potter, P. De Fine-needle Aspiration Biopsy of Suspected Intraocular Tumors. Ophthalmology 1993, 100, 1677–1684.
  38. Schick, U.; Lermen, O.; Hassler, W. Management of Orbital Metastases. Zentralbl. Neurochir. 2006, 67, 1–7.
  39. Martel, A.; Baillif, S.; Nahon-Esteve, S.; Gastaud, L.; Bertolotto, C.; Lassalle, S.; Lagier, J.; Hamedani, M.; Poissonnet, G. Orbital exenteration: An updated review with perspectives. Surv. Ophthalmol. 2021, 66, 856–876.
  40. Traylor, J.I.; Christiano, L.D.; Esmaeli, B.; Hanasono, M.M.; Yu, P.; Suki, D.; Zhang, W.; Raza, S.M.; Hanna, E.Y.; DeMonte, F. Outcomes of orbital exenteration for craniofacial lesions. Cancer 2021, 127, 2465–2475.
  41. Montejano-Milner, R.; López-Gaona, A.; Fernández-Pérez, P.; Sánchez-Orgaz, M.; Romero-Martín, R.; Arbizu-Duralde, A. Orbital metastasis: Clinical presentation and survival in a series of 11 cases. Arch. Soc. Española Oftalmol. 2020.
  42. Mehta, J.S.; Abou-Rayyah, Y.; Rose, G.E. Orbital Carcinoid Metastases. Ophthalmology 2006, 113, 466–472.
  43. Pontoriero, A.; Iatì, G.; Conti, A.; Minutoli, F.; Bottari, A.; Pergolizzi, S.; de Renzis, C. Treatment of periocular basal cell carcinoma using an advanced stereotactic device. Anticancer Res. 2014, 34, 873–875.
  44. Ferini, G.; Molino, L.; Bottalico, L.; de Lucia, P.; Garofalo, F. A small case series about safety and effectiveness of a hypofractionated electron beam radiotherapy schedule in five fractions for facial non melanoma skin cancer among frail and elderly patients. Rep. Pract. Oncol. Radiother. J. Gt. Cancer Cent. Pozn. Polish Soc. Radiat. Oncol. 2021, 26, 66–72.
  45. Palmisciano, P.; Haider, A.S.; Sabahi, M.; Nwagwu, C.D.; Bin Alamer, O.; Scalia, G.; Umana, G.E.; Cohen-Gadol, A.A.; El Ahmadieh, T.Y.; Yu, K.; et al. Primary Skull Base Chondrosarcomas: A Systematic Review. Cancers 2021, 13, 5960.
  46. Rudoler, S.B.; Shields, C.L.; Corn, B.W.; de Potter, P.; Hyslop, T.; Curran, W.J.; Shields, J.A. Functional vision is improved in the majority of patients treated with external-beam radiotherapy for choroid metastases: A multivariate analysis of 188 patients. J. Clin. Oncol. 1997, 15, 1244–1251.
  47. Mortada, A. Roentgenography in Orbital Metastases by Exophthalmos. Am. J. Ophthalmol. 1968, 65, 48–53.
  48. Conti, A.; Pontoriero, A.; Midili, F.; Iatì, G.; Siragusa, C.; Tomasello, C.; la Torre, D.; Cardali, S.M.; Pergolizzi, S.; de Renzis, C. CyberKnife multisession stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for perioptic meningiomas: Intermediate-term results and radiobiological considerations. Springerplus 2015, 4, 1–8.
  49. Pontoriero, A.; Iatì, G.; Cacciola, A.; Conti, A.; Brogna, A.; Siragusa, C.; Ferini, G.; Davì, V.; Tamburella, C.; Molino, L.; et al. Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost in Patients With Spinal Metastases. Technol. Cancer Res. Treat. 2020, 19, 153303382090444.
  50. Hu, W.; Hu, J.; Gao, J.; Yang, J.; Qiu, X.; Kong, L.; Lu, J.J. Outcomes of orbital malignancies treated with eye-sparing surgery and adjuvant particle radiotherapy: A retrospective study. BMC Cancer 2019, 19, 1–10.
  51. Monroe, A.T.; Bhandare, N.; Morris, C.G.; Mendenhall, W.M. Preventing radiation retinopathy with hyperfractionation. Int. J. Radiat. Oncol. 2005, 61, 856–864.
  52. Palmisciano, P.; Haider, A.S.; Nwagwu, C.D.; Wahood, W.; Aoun, S.G.; Abdullah, K.G.; El Ahmadieh, T.Y. Bevacizumab vs. laser interstitial thermal therapy in cerebral radiation necrosis from brain metastases: A systematic review and meta-analysis. J. Neurooncol. 2021, 154, 13–23.
  53. Wiegel, T.; Bottke, D.; Kreusel, K.-M.; Schmidt, S.; Bornfeld, N.; Foerster, M.H.; Hinkelbein, W. External beam radiotherapy of choroidal metastases-final results of a prospective study of the German Cancer Society (ARO 95-08). Radiother. Oncol. 2002, 64, 13–18.
  54. Munzenrider, J.E. Proton therapy for uveal melanomas and other eye lesions. Strahlenther. Und Onkol. 1999, 175, 68–73.
  55. Hirai, A.; Mizota, A.; Mine, S.; Mizoe, J. Two cases of orbital adenocarcinoma treated with heavy charged carbon particle irradiation. Graefe’s Arch. Clin. Exp. Ophthalmol. 2005, 243, 610–614.
  56. Tubin, S.; Gupta, S.; Grusch, M.; Popper, H.H.; Brcic, L.; Ashdown, M.L.; Khleif, S.N.; Peter-Vörösmarty, B.; Hyden, M.; Negrini, S.; et al. Shifting the Immune-Suppressive to Predominant Immune-Stimulatory Radiation Effects by SBRT-PArtial Tumor Irradiation Targeting HYpoxic Segment (SBRT-PATHY). Cancers 2020, 13, 50.
  57. Ferini, G.; Valenti, V.; Tripoli, A.; Illari, S.I.; Molino, L.; Parisi, S.; Cacciola, A.; Lillo, S.; Giuffrida, D.; Pergolizzi, S. Lattice or Oxygen-Guided Radiotherapy: What If They Converge? Possible Future Directions in the Era of Immunotherapy. Cancers 2021, 13, 3290.
  58. Peinado, H.; Zhang, H.; Matei, I.R.; Costa-Silva, B.; Hoshino, A.; Rodrigues, G.; Psaila, B.; Kaplan, R.N.; Bromberg, J.F.; Kang, Y.; et al. Pre-metastatic niches: Organ-specific homes for metastases. Nat. Rev. Cancer 2017, 17, 302–317.
  59. Park, K.; Bae, G.H.; Kim, W.K.; Yoo, C.-J.; Park, C.W.; Kim, S.-K.; Cha, J.; Kim, J.W.; Jung, J. Radiotherapy for brain metastasis and long-term survival. Sci. Rep. 2021, 11, 1–8.
  60. Palmisciano, P.; El Ahmadieh, T.Y.; Haider, A.S.; Bin Alamer, O.; Robertson, F.C.; Plitt, A.R.; Aoun, S.G.; Yu, K.; Cohen-Gadol, A.; Moss, N.S.; et al. Thalamic gliomas in adults: A systematic review of clinical characteristics, treatment strategies, and survival outcomes. J. Neurooncol. 2021, 155, 215–224.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology; Surgery; Ophthalmology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Paolo Palmisciano
View Times: 317
Revisions: 2 times (View History)
Update Date: 12 Jan 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback